Arjun Balar, MD, NYU Langone Health Perlmutter Cancer Center, New York City, NY, discusses systemic treatment versus intravesical treatment of patients with non-muscle-invasive bladder cancer (NMIBC). Dr Balar outlines the benefits of using systemic therapies such as PD-1 targeting antibodies, and highlights increased reliability of systemic immunotherapies versus intravesical approaches. This interview took place during the 2021 Genitourinary Cancers Symposium.